This was a phase 1 study (NCT02695550) to determine the safety, maximum tolerated dose (MTD), pharmacokinetic (PK), and anti-tumor activity of conteltinib in patients with advanced ALK-positive NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.